SLC5A2 and heart failure: These trials aim to extend the established benefits of SGLT2 inhibitors in chronic heart failure and diabetes to the high-risk post-infarction setting, a population traditionally vulnerable to adverse remodeling and subsequent heart failure development [37,38].